CN111565726A - 通过激活α蛋白激酶1调节免疫应答的组合物和方法 - Google Patents

通过激活α蛋白激酶1调节免疫应答的组合物和方法 Download PDF

Info

Publication number
CN111565726A
CN111565726A CN201880081664.1A CN201880081664A CN111565726A CN 111565726 A CN111565726 A CN 111565726A CN 201880081664 A CN201880081664 A CN 201880081664A CN 111565726 A CN111565726 A CN 111565726A
Authority
CN
China
Prior art keywords
compound
alpk1
virus
adp
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880081664.1A
Other languages
English (en)
Chinese (zh)
Inventor
T·徐
许枞
刘丹阳
范洁清
潘延芳
T·R·李
X·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Drug Ranch
Original Assignee
Shanghai Yao Yuan Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yao Yuan Biotechnology Co ltd filed Critical Shanghai Yao Yuan Biotechnology Co ltd
Publication of CN111565726A publication Critical patent/CN111565726A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201880081664.1A 2017-10-27 2018-10-25 通过激活α蛋白激酶1调节免疫应答的组合物和方法 Pending CN111565726A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/107962 2017-10-27
CNPCT/CN2017/107962 2017-10-27
CNPCT/CN2018/083153 2018-04-16
CNPCT/CN2018/083153 2018-04-16
CNPCT/CN2018/100871 2018-08-16
CNPCT/CN2018/100871 2018-08-16
PCT/CN2018/111885 WO2019080898A1 (en) 2017-10-27 2018-10-25 COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE RESPONSE BY ACTIVATION OF PROTEIN KINASE ALPHA 1

Publications (1)

Publication Number Publication Date
CN111565726A true CN111565726A (zh) 2020-08-21

Family

ID=66246202

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880081664.1A Pending CN111565726A (zh) 2017-10-27 2018-10-25 通过激活α蛋白激酶1调节免疫应答的组合物和方法

Country Status (8)

Country Link
US (5) US11186606B2 (enExample)
EP (1) EP3700536A4 (enExample)
JP (2) JP2021500394A (enExample)
KR (1) KR102733555B1 (enExample)
CN (1) CN111565726A (enExample)
AU (1) AU2018355487B2 (enExample)
CA (1) CA3078267C (enExample)
WO (1) WO2019080898A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116808216A (zh) * 2022-07-06 2023-09-29 四川大学 Alpk1基因作为脑缺血导致的中枢神经系统疾病的防治靶点的应用
CN117517657A (zh) * 2024-01-08 2024-02-06 中国农业科学院北京畜牧兽医研究所 Lnx1基因或蛋白在调控禽类先天免疫应答反应中的应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
BR112017028316A2 (en) 2015-06-30 2018-09-04 Sanford-Burnham Medical Research Institute btla fusion protein agonists and uses thereof
KR102733555B1 (ko) 2017-10-27 2024-11-25 상하이 야오 유안 바이오테크놀로지 컴퍼니 리미티드 알파 단백질 키나제 1의 활성화에 의해 면역 반응을 조절하는 조성물 및 방법
WO2019238024A1 (en) 2018-06-14 2019-12-19 National Institute Of Biological Sciences, Beijing Promoting immune responses
EP3958870A1 (en) * 2019-04-26 2022-03-02 Shanghai Yao Yuan Biotechnology Co., Ltd. Derivatives of glycero-manno-heptose adp for use in modulating immune response
WO2021231436A1 (en) * 2020-05-11 2021-11-18 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic methods for treating covid-19 infections
WO2022035917A1 (en) * 2020-08-14 2022-02-17 Merck Sharp & Dohme Corp. Synthesis of fluorinated nucleotides
WO2022127914A1 (en) 2020-12-18 2022-06-23 Pyrotech (Beijing) Biotechnology Co., Ltd. Nucleoside-thiodiphosphate-heptose compounds for treating conditions associated with alpk1 activity
CA3233387A1 (en) 2021-09-30 2023-04-06 Nana Du Nucleoside-diphosphate-heptose compounds for treating conditions associated with alpk1 activity
WO2025113626A2 (en) 2023-11-30 2025-06-05 Pyrotech (Beijing) Biotechnology Co., Ltd. Salt forms of alpk1 activators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101340918A (zh) * 2005-12-19 2009-01-07 阿特纳赞塔里斯有限公司 具有降低细胞毒性的新烷基磷脂衍生物及其用途
US20100016250A1 (en) * 2006-04-14 2010-01-21 Kyowa Hakko Kirin Co., Ltd. Toll-like receptor 9 agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE7611930U1 (de) 1976-04-15 1977-01-13 Filterwerk Mann & Hummel Gmbh, 7140 Ludwigsburg Vorrichtung zum mischen von koernigem oder pulverfoermigem material mit einem oder mehreren zusatzstoffen
GB2432834A (en) 2004-01-12 2007-06-06 Cytopia Res Pty Ltd Selective Kinase Inhibitors
TW200923103A (en) 2007-09-10 2009-06-01 Nat Health Research Institutes ALPK1 gene variants in diagnosis risk of gout
PL2303264T3 (pl) 2008-06-09 2018-08-31 Allergan, Inc. Sposoby leczenia stanów pośredniczonych alfa-adrenergicznie z użyciem pochodnych imidazoliny
CN201735264U (zh) 2010-05-27 2011-02-09 蓝星化工有限责任公司 一种尘降器
CN202590724U (zh) 2010-12-20 2012-12-12 西安磁林电气有限公司 一种加料装置
EP3778896A1 (en) 2011-08-09 2021-02-17 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
EP2867237A1 (en) 2012-06-27 2015-05-06 4SC Discovery GmbH Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
GB201408100D0 (en) 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
CN204182373U (zh) 2014-09-30 2015-03-04 天津博弘化工有限责任公司 流化床下料斗排气装置
EP3204014B1 (en) 2014-10-10 2020-07-01 The Governing Council of the University of Toronto Methods of modulating immune system responses
CN204973750U (zh) 2015-05-26 2016-01-20 柳州钢铁股份有限公司 圆筒混合机刮料器
EP3190062A1 (en) 2016-01-07 2017-07-12 Pont Packaging B.V. A cap construction with a storage space and a container provided therewith as well as a method of using same
CN105536635A (zh) 2016-02-02 2016-05-04 珠海格力智能装备有限公司 一种车用尿素加料装置
CN206366365U (zh) 2016-12-13 2017-08-01 珠海格力智能装备有限公司 吸料装置及具有其的尿素机
CN106582336B (zh) 2016-12-13 2022-09-13 珠海格力智能装备有限公司 吸料装置及具有其的尿素机
KR102733555B1 (ko) 2017-10-27 2024-11-25 상하이 야오 유안 바이오테크놀로지 컴퍼니 리미티드 알파 단백질 키나제 1의 활성화에 의해 면역 반응을 조절하는 조성물 및 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101340918A (zh) * 2005-12-19 2009-01-07 阿特纳赞塔里斯有限公司 具有降低细胞毒性的新烷基磷脂衍生物及其用途
US20100016250A1 (en) * 2006-04-14 2010-01-21 Kyowa Hakko Kirin Co., Ltd. Toll-like receptor 9 agonists

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116808216A (zh) * 2022-07-06 2023-09-29 四川大学 Alpk1基因作为脑缺血导致的中枢神经系统疾病的防治靶点的应用
CN117517657A (zh) * 2024-01-08 2024-02-06 中国农业科学院北京畜牧兽医研究所 Lnx1基因或蛋白在调控禽类先天免疫应答反应中的应用
CN117517657B (zh) * 2024-01-08 2024-04-09 中国农业科学院北京畜牧兽医研究所 Lnx1基因或蛋白在调控禽类先天免疫应答反应中的应用

Also Published As

Publication number Publication date
KR102733555B1 (ko) 2024-11-25
US20220017560A1 (en) 2022-01-20
US20200283468A1 (en) 2020-09-10
AU2018355487B2 (en) 2023-09-21
EP3700536A1 (en) 2020-09-02
AU2018355487A1 (en) 2020-04-23
JP2021500394A (ja) 2021-01-07
JP2023182695A (ja) 2023-12-26
CA3078267C (en) 2024-06-18
US20190367553A1 (en) 2019-12-05
US11773131B2 (en) 2023-10-03
AU2018355487A2 (en) 2020-05-21
US20240124511A1 (en) 2024-04-18
US20210403501A1 (en) 2021-12-30
WO2019080898A1 (en) 2019-05-02
US11840551B2 (en) 2023-12-12
US11149051B2 (en) 2021-10-19
US11186606B2 (en) 2021-11-30
KR20200090154A (ko) 2020-07-28
EP3700536A4 (en) 2021-11-17
CA3078267A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
CN111565726A (zh) 通过激活α蛋白激酶1调节免疫应答的组合物和方法
TWI825170B (zh) 抗體藥物結合物及其應用及用途
AU2021221986B2 (en) Antiviral compounds
EP3727401A1 (en) Cyclic di-nucleotide compounds as sting agonists
EP3752516B1 (en) Cyclic dinucleotides as anticancer agents
AU2021224588B2 (en) Antiviral compounds
CN114025771A (zh) 用于调节免疫反应的甘油-甘露-庚糖adp衍生物
CA3233387A1 (en) Nucleoside-diphosphate-heptose compounds for treating conditions associated with alpk1 activity
KR20220012241A (ko) 글리세로-만노-헵토스 포스페이트의 유도체 및 면역 반응 조절시의 이의 용도
KR20230107586A (ko) 다기능성 사이클릭 디뉴클레오티드 및 이의 용도
TWI905974B (zh) 抗體藥物結合物之用途
RU2809547C2 (ru) Новое производное циклического динуклеотида и его конъюгат антитело-лекарственное средство
HK40081401A (en) Antiviral compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: China

Address after: Building 5, No. 69 Yuanfeng Road, Baoshan District, Shanghai, 200444

Applicant after: SHANGHAI YAO YUAN BIOTECHNOLOGY Co.,Ltd.

Address before: 200437 room 701, floor 7, No. 43, Handan Road, Hongkou District, Shanghai

Applicant before: SHANGHAI YAO YUAN BIOTECHNOLOGY Co.,Ltd.

Country or region before: China

TA01 Transfer of patent application right

Effective date of registration: 20250106

Address after: Building 5, No. 69 Yuanfeng Road, Baoshan District, Shanghai, 200444

Applicant after: Drug Ranch

Country or region after: Cayman Islands

Address before: Building 5, No. 69 Yuanfeng Road, Baoshan District, Shanghai, 200444

Applicant before: SHANGHAI YAO YUAN BIOTECHNOLOGY Co.,Ltd.

Country or region before: China

TA01 Transfer of patent application right
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250423

Address after: Building D7, No. 555 Chuangye Road, Dayun Town, Jiashan County, Jiaxing City, Zhejiang Province, China 314113

Applicant after: Zhejiang Pharmaceutical Garden Biotechnology Co.,Ltd.

Country or region after: China

Address before: Building 5, No. 69 Yuanfeng Road, Baoshan District, Shanghai, 200444

Applicant before: Drug Ranch

Country or region before: Cayman Islands

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250512

Address after: Building 5, No. 69 Yuanfeng Road, Baoshan District, Shanghai, 200444

Applicant after: SHANGHAI YAO YUAN BIOTECHNOLOGY Co.,Ltd.

Country or region after: China

Address before: Building D7, No. 555 Chuangye Road, Dayun Town, Jiashan County, Jiaxing City, Zhejiang Province, China 314113

Applicant before: Zhejiang Pharmaceutical Garden Biotechnology Co.,Ltd.

Country or region before: China

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250523

Address after: Building 5, No. 69 Yuanfeng Road, Baoshan District, Shanghai, 200444

Applicant after: Drug Ranch

Country or region after: Cayman Islands

Address before: Building 5, No. 69 Yuanfeng Road, Baoshan District, Shanghai, 200444

Applicant before: SHANGHAI YAO YUAN BIOTECHNOLOGY Co.,Ltd.

Country or region before: China